EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
The European Commission approved Amgen's IMDYLLTRA for extensive-stage small cell lung cancer, based on Phase 3 DeLLphi-304 trial data showing a 40% reduction in risk of death versus chemotherapy. This approval represents a novel treatment option for patients with progressive disease.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
European Commission approval for extensive-stage small cell lung cancer based on Phase 3 DeLLphi-304 trial showing 40% reduction in risk of death compared to chemotherapy
Importance:8/10
Sentiment:
0.90
regulatory_approvaleuropean_commissionlung_cancerphase_3oncology
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on June 1, 2026 8:00 PM